AJGP
HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a Colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lu, C.-j.
Right arrow Articles by Tune, L. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, C.-j.
Right arrow Articles by Tune, L. E.
Am J Geriatr Psychiatry 11:458-461, August 2003
© 2003 American Association for Geriatric Psychiatry

Brief Report

Chronic Exposure to Anticholinergic Medications Adversely Affects the Course of Alzheimer Disease

Ching-ju Lu, B.A., and Larry E. Tune, M.D.

Received October 29, 2002; revised March 20, 2003; accepted April 4, 2003. From the Department of Psychiatry at Wesley Woods Geriatric Teaching and Research Hospital, Emory University School of Medicine, Atlanta, Georgia. Address correspondence to Dr. Tune, Department of Psychiatry, Wesley Woods Geriatric Teaching and Research Hospital, 1841 Clifton Rd. NE, Emory University School of Medicine, Atlanta, GA 30329-5102. e-mail: ltune{at}emory.edu

Objective: Authors examined the effect of chronic exposure to anticholinergics in a cohort of Alzheimer disease (AD) patients. Methods: All patients were examined annually with standard neuropsychologic tests and received the cholinesterase inhibitor donepezil hydrochloride at a dose of 10 mg/day. The study population (N=69) was divided into two groups: those receiving one or more concomitant medications with significant anticholinergic properties (N=16) and those receiving no concomitant medications with anticholinergic properties (N=53). Results: At 2 years, MMSE scores were significantly worse for patients receiving anticholinergic medications than for those not on anticholinergics. Conclusion: Although very preliminary, these data suggest that concomitant therapy with anticholinergics may be associated with significant deleterious effects on acetylcholinesterase therapy, or, more speculatively, that chronic exposure to anticholinergics may have adverse effects on the clinical course of AD.

Key Words: Anticholinergics • Alzheimer Disease






HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH TABLE OF CONTENTS
Copyright © 2003 American Association for Geriatric Psychiatry